Kezar Life Sciences, Inc.
Kezar Life Sciences, Inc.（KZR）股价预测与分析师目标价
华尔街共识、12 个月目标价、模型推演与 EPS/营收预期 — 来自分析师数据与历史行情。
kzr · 股价预测 · 7 位分析师（近3月）· FMP · 更新于 2026年5月20日
分析师评级与共识
基于过去 3 个月内 7 位华尔街分析师
Hold
7 位分析师
共识
评级分布
12 个月目标价
High
$21.00
Consensus
$11.00
+50.9% upside
Low
$5.00
Median: $7 · Last Close: $7.29
12 个月目标价预测
历史收盘价 + 分析师 12 个月目标价预测区间
Consensus Target
$11.00
50.9% upside
High Target
$21
188.1%
Low Target
$5
-31.4%
Current Price
$7.29
as of today
Based on analyst price targets, the KZR stock price prediction for the next 12 months ranges from $5 to $21. The consensus KZR price forecast of $11.00 implies 50.9% upside from the current price of $7.29.
短期股价预测
Low Activity算法生成 · 每日更新
| Date | Predicted Price | Change |
|---|---|---|
| 2026-06-10 | $7.29 | ↑ 0.04% |
1-day model range: $7.28–$7.31. Peak: $7.31 (+0.04%).
长期股价预测
基于技术分析的股价预测
14 项技术面信号（SMA×6 + EMA×6 + RSI + MACD）· EEAT 方法论透明
Insufficient Trading Activity — Sentiment Signals Disabled
This stock has very low trading volume (ZOMBIE condition). Sentiment analysis requires sufficient price action. RSI and MACD values below are still shown for reference.
Moving Averages · KZR · Jun 9, 2026
最新分析师评级与调整
| Date | Brokerage | Action | Rating |
|---|---|---|---|
| 2025-10-17 | Wells Fargo | Maintains | Equal Weight→Equal Weight |
| 2025-10-17 | Jefferies | Downgrade ↓ | Buy→Hold |
| 2025-10-17 | William Blair | Downgrade ↓ | Outperform→Market Perform |
| 2025-07-16 | HC Wainwright & Co. | Maintains | Neutral→Neutral |
| 2024-12-19 | Wells Fargo | Maintains | Equal Weight→Equal Weight |
| 2024-12-02 | HC Wainwright & Co. | Maintains | Neutral→Neutral |
| 2024-11-14 | Wells Fargo | Maintains | Equal Weight→Equal Weight |
| 2024-10-02 | HC Wainwright & Co. | Downgrade ↓ | Buy→Neutral |
| 2024-08-14 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2024-07-22 | HC Wainwright & Co. | Maintains | Buy→Buy |
Wall Street analysts have recently issued updated ratings on Kezar Life Sciences, Inc. (KZR) stock. Of the recent 41 rating actions, 0 were upgrades and 6 were downgrades. 7 analysts currently cover KZR.
分析师推荐趋势
KZR analyst recommendation trends show decreasing buy-side sentiment over the past 6 months. Buy rating actions changed from 1 to 0 per month.
财务预测：EPS 与营收一致预期
Revenue This Year
$0M
↓ 100.0% YoY
Revenue Next Year
$21M
EPS This Year
$-4.93
EPS Next Year
$-6.89
↑ 39.8% YoY
EPS ForecastReported vs Estimated
Analysts forecast KZR EPS of $-4.93 for the current fiscal year, based on estimates from 1 analysts. The KZR revenue forecast is $0M for the current year. These are analyst consensus estimates via FMP / S&P Global.
关于预测与目标价
KZR 股价预测由两类独立数据源支撑：来自 7 位华尔街分析师（S&P Global / FMP）的共识评级，以及基于历史日终价计算的技术分析。KZR 的共识目标价为 $11.00（+50.9% 上行空间），分析师共识为 Hold。
KZR 的短期预测（明日）为 $7.29（+0.04%）。
Kezar Life Sciences, Inc. 在 NASDAQ 上市，代码 KZR。KZR 在 2027 年的整体展望偏中性/分化，在覆盖分析师中约 29% 对应 Hold 共识。
常见问题
KZR 预测 · 8 个问题根据 7 位华尔街分析师，KZR 的 12 个月平均目标价为 $11.00，最高 $21.00、最低 $5.00。若有图表，中位目标价可在上方查看。相对当前价 $7.29，隐含约 +50.9% 的上行空间。
· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)
⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.